Here's the Bigger Story About Moderna That You Might Be Missing
Ask most people about Moderna (NASDAQ: MRNA) and you're likely to get one of two responses. Many individuals won't recognize the company's name at all. Of those that do, they'll probably mention that Moderna is one of the leaders in the race to develop a COVID-19 vaccine.
That's definitely Moderna's greatest claim to fame right now. There are only four coronavirus vaccines in late-stage testing in the U.S. right now (including AstraZeneca's paused study). Moderna's mRNA-1273 is one of them.
Investors' excitement about the potential for mRNA-1273 is the main reason behind the biotech stock soaring close to 250% so far this year. But there's a bigger story about Moderna that you might be missing. And it's one that could mean that the company's gains in 2020 are merely a drop in the bucket of what's to come.
Source Fool.com
